Table 1.

Sample characteristics

MEASURE	N (%) or Mean (SD)
STUDY 1	147 (100%)
Gender
Male	88 (59.9%)
Female	59 (40.1%)
Ethnicity
Caucasian	88 (59.9%)
Black	24 (16.3%)
Hispanic	21 (14.3%)
Asian	11 (7.5%)
Other	3 (2.0%)
Age (at enrollment)	54.6 (10.8)
Treatment Assignment
Sitagliptan	64 (43.5%)
Pioglitazone	44 (29.9%)
Exenatide QW	39 (26.5%)
BMI (kg/m^2)	33.7 (5.3)
A1c	8.5 (1.2)
DTSQs frequency of perceived hyperglycemia (0–6)	2.8 (1.7)
DTSQs frequency of perceived hypoglycemia (0–6)	0.9 (1.5)
WHO-5 Well-Being Index total (0–100)	67.6 (18.1)
EQ-5D Visual Analog Scale (0–100)	76.2 (18.4)
EQ-5D Item 3 – Usual Activities (1–3, higher score = more problems)	1.2 (0.4)
IWQOL-Lite total score (0–100)	82.6 (15.5)
STUDY 2	93 (100%)
Gender
Male	61 (65.6%)
Female	32 (34.4%)
Ethnicity
Caucasian	76 (81.7%)
Black	12 (12.9%)
Other	5 (5.4%)
Age (at enrollment)	50.8 (10.5)
Medication (at enrollment)
Metformin only	61 (65.6%)
Metformin and TZD	10 (10.8%)
TZD only	1 (1.0%)
None	21 (22.6)
Treatment assignment (Exenatide dose)
2 mg, once weekly	22 (23.7%)
5 mg, once monthly	22 (23.7%)
8 mg, once monthly	26 (28.0%)
11 mg, once monthly	23 (24.7%)
Baseline BMI (kg/m^2)	34.1 (5.7)
Baseline A1c	8.3 (1.1)
Baseline DTSQs perceived hyperglycemia	2.8 (1.9)
Baseline DTSQs perceived hypoglycemia	1.0 (1.3)
Change from baseline in BMI (kg/m^2)	−0.4 (5.3)***
Change from baseline in A1c	−1.2 (1.2)***
Change from baseline in DTSQs perceived hyperglycemia	−1.1 (2.1)***
Change from baseline in DTSQs perceived hypoglycemia	0.2 (1.6)

BMI, body mass index; A1c, glycated hemoglobin; SD, standard deviation; *** p <; 0.001 (two-tailed).